Atea Pharmaceuticals (AVIR) Interest & Investment Income (2020 - 2022)
Historic Interest & Investment Income for Atea Pharmaceuticals (AVIR) over the last 3 years, with Q4 2022 value amounting to $5.6 million.
- Atea Pharmaceuticals' Interest & Investment Income rose 1086274.51% to $5.6 million in Q4 2022 from the same period last year, while for Dec 2022 it was $11.2 million, marking a year-over-year increase of 511074.77%. This contributed to the annual value of $25.5 million for FY2024, which is 1277.72% down from last year.
- As of Q4 2022, Atea Pharmaceuticals' Interest & Investment Income stood at $5.6 million, which was up 1086274.51% from $4.4 million recorded in Q3 2022.
- In the past 5 years, Atea Pharmaceuticals' Interest & Investment Income ranged from a high of $5.6 million in Q4 2022 and a low of $7000.0 during Q3 2020
- Over the past 3 years, Atea Pharmaceuticals' median Interest & Investment Income value was $53000.0 (recorded in 2021), while the average stood at $1.0 million.
- Data for Atea Pharmaceuticals' Interest & Investment Income shows a peak YoY increase of 1086274.51% (in 2022) and a maximum YoY decrease of 6896.55% (in 2022) over the last 5 years.
- Atea Pharmaceuticals' Interest & Investment Income (Quarter) stood at $9000.0 in 2020, then surged by 466.67% to $51000.0 in 2021, then soared by 10862.75% to $5.6 million in 2022.
- Its last three reported values are $5.6 million in Q4 2022, $4.4 million for Q3 2022, and $1.1 million during Q2 2022.